Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder

• Status: Unknown status
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to identify evidence-based guidelines for treating major depressive disorder to full remission in Taiwanese major depressive disorder (MDD) patients. To achieve this goal, the investigators aim to: (1) evaluate the risks and benefits of adjunctive pharmacotherapies for cognitive and metabolic consequences in MDD, and (2) clarify the shared biological mechanisms between mood, immune and metabolism homeostasis

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cheng-Kung University Hospital
• Collaborator: National Science Council, Taiwan
• Treatments: Fluoxetine; Insulin; Valsartan

Criteria

Inclusion Criteria:

• Age: 16-65 years old

• Signed informed consent by patient or legal representative

• Hamilton Rating Scale for Depression (HDRS) scores ≥ 16

• A diagnosis of MDD according to DSM-IV criteria made by a specialist in psychiatry

Exclusion Criteria:

• Monoamine oxidase inhibitor or antidepressant treatment prior to entering the study

• A DSM-IV diagnosis of substance abuse within the past three months

• An organic mental disease, mental retardation or dementia

• A serious surgical condition or physical illness

• Patients who were pregnant or breastfeeding